Background. Introduction of drug-eluting stent (DES) dramatically reduced major acute cardiac events (MACE) and restenosis. Many centers still practice scheduled angiographic follow-up (Angio-F/U) after DES treatment. We investigated real world MACE and restenosis rate after DES treatment to find out the necessity and efficacy of scheduled Angio-F/U. Method and Results. Pooled registry data from April 2003 to January 2005 were used. DESs were implanted on 2121 lesions of 1638 patients (Sirolimus-eluting stent, SES 1442, paclitaxel-eluting stent, PES 679). Scheduled Angio F/U was done in 570 patients (34.8%, 677 stents). Total MACE occurred in 76 patients (4.6% SES 40, 3.5%, PES 36, 7.3%, NS). Deaths were occurred in 26 patients. There were 8 cases of non-fatal myocardial infarction including 4 subacute thrombosis cases. Target lesion revascularization (TLR) was done in 46 patients, 50 lesions. Of all TLR cases 13 patients had coronary symptoms. Other 33 patients had no clinical symptoms at the time of TLR (33/570, 5.8%). Angiographic characteristics of these patients include 13 diffuse long lesions, 10 chronic total occlusion, and 7 in-stent restenosis. Atherosclerotic risk factors were 21 HTN, 9 DM, 9 hypercholesterolemia, 5 smokers, and 3 CRF. Fourteen patients had multiple risk factors. Conclusion. In DES era, routine scheduled Angio-F/U has low efficacy. But scheduled Angio-F/U is still useful in patients with high-risk angiographic characteristics and/or multiple atherosclerotic risk factors.